Thursday, May 6, 2021 · 4:30pm ET
Download Investor Presentation
Evofem Biosciences, Inc. (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs).
The Company launched it's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), in September 2020. Phexxi is the first and only hormone-free, prescription contraceptive vaginal gel. Learn more at phexxi.com.
The Company is evaluating its investigational drug candidate EVO100 vaginal gel for the prevention of urogenital transmission of chlamydia and gonorrhoea in women. Enrollment is underway in EVOGUARD, a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of EVO100 for the prevention of these common STIs. Top-line results are expected in mid-2022.
EVOGUARD builds on positive, statistically significant results of a double-blind placebo-controlled Phase 2b clinical trial (AMPREVENCE). This landmark study met its primary and secondary endpoints, demonstrating a 50% relative risk reduction in chlamydia infection and a 78% relative risk reduction in gonorrhea infection compared to placebo. The AMPREVENCE manuscript was published in the presigious peer-reviewed journal American Journal of Obstetrics and Gynecology in 2021.